Andusomeran API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Andusomeran API 2918977-08-7?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Andusomeran. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Andusomeran
- Synonyms:
- COVID-19 mRNA vaccine, monovalent (XBB.1.5 Variant) , CX-038839 Omicron (XBB.1.5)
- Cas Number:
- 2918977-08-7
- DrugBank number:
- DB18227
- Unique Ingredient Identifier:
- 4F9QRS7ZV2
General Description:
Andusomeran, identified by CAS number 2918977-08-7, is a notable compound with significant therapeutic applications. Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season. It is similar to previous mRNA vaccines developed by Moderna (e.g. , ), but is designed to be effective against the Omicron XBB.1.5 subvariant.
Indications:
This drug is primarily indicated for: Andusomeran is indicated for the prevention of COVID-19 caused by SARS-CoV-2. It is intended to elicit protection against the Omicron XBB.1.5 subvariant. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Pharmacodynamics:
Andusomeran exerts its therapeutic effects through: The safety and efficacy of andusomeran are primarily inferred from studies of the original Spikevax vaccine () and a previously approved bivalent vaccine (elasomeran and ). The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Andusomeran functions by: Moderna's COVID-19 mRNA vaccine is composed of synthetic nucleoside-modified messenger RNA (mRNA) encapsulated in lipid nanoparticle (LNP) which codes for the full-length, pre-fusion stabilized spike protein (S) of SARS-CoV-2. The S glycoprotein is a large transmembrane protein that plays a critical role in viral attachment, fusion, and entry into the host cell. Upon vaccination, human cells express the SARS-CoV-2 S antigen and immune response to the S antigen is elicited, leading to protection against SARS-CoV-2. Andusomeran is a COVID-19 mRNA vaccine that encodes for the pre-fusion stabilized S glycoprotein of the SARS-CoV-2 Omicron subvariant XBB.1.5 (containing mutations K982P and V983P) which is intended to elicit protection against this variant. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Categories:
Andusomeran is categorized under the following therapeutic classes: COVID-19 Vaccines, mRNA Vaccines, Vaccines, Viral Vaccines. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
